智通财经APP讯,佰仁医疗(688198.SH)发布公告,近日,公司自主研发的射频消融系统获国家药品监督管理局医疗器械技术审评中心同意,进入创新医疗器械特别审查程序。
该射频消融系统由消融仪、消融钳和消融笔三个产品组成,专用于心外科手术治疗持续性、永久性房颤。该产品是按照传统迷宫手术原理,采用心外直视手术的方式,对心房组织进行电隔离,即创建透壁、连续、不可逆的线性损伤,从而达到消除房颤触发灶和维持基质,以达到恢复窦性心律的目的。
智通财经APP讯,佰仁医疗(688198.SH)发布公告,近日,公司自主研发的射频消融系统获国家药品监督管理局医疗器械技术审评中心同意,进入创新医疗器械特别审查程序。
该射频消融系统由消融仪、消融钳和消融笔三个产品组成,专用于心外科手术治疗持续性、永久性房颤。该产品是按照传统迷宫手术原理,采用心外直视手术的方式,对心房组织进行电隔离,即创建透壁、连续、不可逆的线性损伤,从而达到消除房颤触发灶和维持基质,以达到恢复窦性心律的目的。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.